125 related articles for article (PubMed ID: 15833553)
1. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.
Seargent JM; Loadman PM; Martin SW; Naylor B; Bibby MC; Gill JH
Urology; 2005 Apr; 65(4):815-20. PubMed ID: 15833553
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
[TBL] [Abstract][Full Text] [Related]
3. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Yoshida O
J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
[TBL] [Abstract][Full Text] [Related]
4. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
5. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.
Boorjian S; Ugras S; Mongan NP; Gudas LJ; You X; Tickoo SK; Scherr DS
Urology; 2004 Aug; 64(2):383-8. PubMed ID: 15302512
[TBL] [Abstract][Full Text] [Related]
7. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
Davies B; Waxman J; Wasan H; Abel P; Williams G; Krausz T; Neal D; Thomas D; Hanby A; Balkwill F
Cancer Res; 1993 Nov; 53(22):5365-9. PubMed ID: 8221672
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder.
Yamasaki Y; Smith C; Weisz D; van Huizen I; Xuan J; Moussa M; Stitt L; Hideki S; Cherian MG; Izawa JI
Urology; 2006 Mar; 67(3):530-5. PubMed ID: 16504266
[TBL] [Abstract][Full Text] [Related]
9. Translational studies of glutathione in bladder cancer cell lines and human specimens.
Pendyala L; Velagapudi S; Toth K; Zdanowicz J; Glaves D; Slocum H; Perez R; Huben R; Creaven PJ; Raghavan D
Clin Cancer Res; 1997 May; 3(5):793-8. PubMed ID: 9815751
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
[TBL] [Abstract][Full Text] [Related]
11. [Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation].
Zhang HP; Yu B; Zheng XD; Hu HJ; Gao ZB; Li L; Zhou LF
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):1011-4. PubMed ID: 19102503
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter.
Kamijima S; Tobe T; Suyama T; Ueda T; Igarashi T; Ichikawa T; Ito H
Int J Urol; 2005 Nov; 12(11):941-7. PubMed ID: 16351648
[TBL] [Abstract][Full Text] [Related]
14. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
15. [Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof].
Yu L; Chen XJ; Shi PQ; Ding Q; Sun CH; Liu GB; Shi DM; Huang YG
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2683-4. PubMed ID: 19080686
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases may contribute compensationally to tumor invasion in T1 colorectal carcinomas.
Masaki T; Sugiyama M; Matsuoka H; Abe N; Izumisato Y; Sakamoto A; Atomi Y
Anticancer Res; 2003; 23(5b):4169-73. PubMed ID: 14666620
[TBL] [Abstract][Full Text] [Related]
17. Relationship between cysteinyl-leukotriene-1 receptor and human transitional cell carcinoma in bladder.
Matsuyama M; Funao K; Hayama T; Tanaka T; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
Urology; 2009 Apr; 73(4):916-21. PubMed ID: 19167045
[TBL] [Abstract][Full Text] [Related]
18. [Expression of cyclooxygenase in bladder transitional cell carcinoma].
Wang KJ; Li H; Wei Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):54-6. PubMed ID: 14981815
[TBL] [Abstract][Full Text] [Related]
19. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
20. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
